Humanin: Mitochondrial Peptide, No Human Trials

TL;DR

Humanin is a tiny peptide made from mitochondrial DNA, first found because it protected brain cells from Alzheimer's-related damage in a lab dish. Researchers can measure it in human blood, and levels do shift with age and disease, but that is only an observation, not proof it does anything if you inject it. Nobody has run a human clinical trial giving people Humanin. Everything on this page beyond the blood-level observations is cell and animal research only.

What is Humanin?

Humanin is a small, mitochondria-derived peptide, originally identified as a 24-amino-acid sequence encoded within the mitochondrial 16S rRNA gene region (the MT-RNR2 / humanin-like open reading frame). It was discovered by Hashimoto and colleagues in 2001 through an expression screen designed to find factors capable of protecting neurons against Alzheimer's disease-related insults, specifically toxicity induced by amyloid-beta — this discovery work was published in Proceedings of the National Academy of Sciences (PNAS). Humanin belongs to a broader class now referred to as mitochondrial-derived peptides (MDPs), a research area substantially advanced by Pinchas Cohen's laboratory at the University of Southern California. Unlike Tesamorelin, Humanin has essentially no human interventional clinical trial data — research is almost entirely preclinical, drawn from cell culture and rodent models, supplemented by human observational studies correlating circulating Humanin levels with age and disease states. There is no approved therapeutic use for Humanin, and this guide should be read with that important limitation in mind. Not medical advice.

How strong is the evidence?

Evidence Type	Status
Human RCT	✗
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Note: There are essentially no interventional human clinical trials of Humanin. Human evidence is limited to observational and correlational studies measuring circulating Humanin levels against age and disease markers.

How does Humanin work?

Humanin is reported to interact with multiple molecular targets rather than a single dedicated receptor. Research has identified binding interactions with components of the IGF-1 receptor signalling pathway, with the formyl peptide receptor-like 1 (FPRL1, also known as FPR2), and with pro-apoptotic proteins including BAX. Through BAX-binding, Humanin is proposed to interfere with the translocation of BAX to the mitochondrial outer membrane, a key step in the intrinsic apoptotic pathway, thereby limiting mitochondrial-mediated cell death signalling in preclinical models. Because Humanin is itself produced from a mitochondrial gene region, much of the mechanistic research also frames it as a mitochondrial-to-nuclear signalling molecule — part of a "mitochondrial-derived peptide" family proposed to communicate cellular stress status and modulate downstream protective and metabolic signalling pathways, an area of active preclinical investigation rather than an established human physiological mechanism.

What has Humanin been studied for?

Neuroprotection Against Amyloid-Beta Toxicity

The original discovery research by Hashimoto and colleagues demonstrated that Humanin could rescue cultured neurons from cell death induced by a wide spectrum of familial Alzheimer's disease-related genes and by amyloid-beta itself. This founding observation established Humanin's primary research identity as a neuroprotective peptide in cell culture models of Alzheimer's disease-related toxicity.

Cytoprotective and Anti-Apoptotic Mechanisms

Follow-up mechanistic work, including research published by Guo and colleagues, characterised Humanin's interference with BAX activation as a central anti-apoptotic mechanism. This body of in vitro research positions Humanin as a candidate cytoprotective peptide studied across various cell stress and apoptosis models, though this remains preclinical cell-culture work rather than validated therapeutic evidence.

Insulin Sensitivity and Metabolic Research

Pinchas Cohen's laboratory has published extensively on Humanin's role in metabolic regulation, notably Muzumdar and colleagues' 2009 study describing Humanin as a novel central regulator of peripheral insulin action in rodent models. This research area frames Humanin within the broader ageing and metabolism literature, exploring its relationship to insulin sensitivity as animal-model findings rather than confirmed human clinical outcomes.

Mitochondrial Function and Ageing Biomarker Research

As a mitochondrial-derived peptide, Humanin has been studied by Cohen, Lee, Yen and colleagues as part of a research programme examining circulating MDP levels as potential biomarkers of mitochondrial function and biological ageing. Human observational cohorts have reported associations between circulating Humanin levels and age or disease status, though these are correlational findings, not evidence of a therapeutic effect from Humanin administration.

What did the studies actually find?

Study / Model	Reported Effect
Hashimoto Y et al. 2001 — Neuronal culture (PNAS)	Rescued neurons from cell death induced by familial Alzheimer's disease genes and amyloid-beta toxicity (preclinical, in vitro).
Guo B et al. 2003 — Cell culture / apoptosis model (Nature)	Humanin peptide reported to suppress apoptosis by interfering with BAX activation (preclinical, in vitro).
Muzumdar RH et al. 2009 — Rodent model (PLoS ONE)	Central administration reported to regulate peripheral insulin action, described as a novel central regulator of insulin sensitivity (preclinical, animal model).
Human observational cohorts (various, reviewed by Cohen P, Lee C et al.)	Circulating Humanin/MDP levels reported to correlate with age and certain disease states (observational, correlational only — not interventional).

What side effects were reported?

• No human side effect data exists — Humanin has not been tested in human clinical trials
• Preclinical rodent and cell-culture models report good general tolerability
• No major adverse signals reported in the cited preclinical literature

Because Humanin has never progressed to human interventional trials, there is minimal to no human side effect data available. Statements about tolerability are limited to preclinical models and should not be interpreted as evidence of human safety.

Humanin at a glance

CAS Number

328968-31-4

Molecular Formula

C₁₁₉H₁₈₅N₃₃O₄₀ (24-mer peptide, sequence MAPRGFSCLLLLTSEIDLPVKRRA)

Molecular Weight

Approximately 2687.0 g/mol (variable by isoform/analogue)

Half-Life

Very short in vivo (minutes) — a limitation that has led to research into more stable analogues such as S14G-Humanin (HNG) and colivelin

Synonyms

MT-RNR2, HN, S14G-Humanin (HNG) analogue, colivelin (fusion analogue)

Research Classification

Mitochondrial-Derived Peptide (MDP), Cytoprotective/Anti-Apoptotic Peptide

The research this page cites

• Hashimoto Y et al. 2001 — A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. — Proceedings of the National Academy of Sciences (PNAS) — [In Vitro]
• Guo B et al. 2003 — Humanin peptide suppresses apoptosis by interfering with Bax activation. — Nature — [In Vitro]
• Muzumdar RH et al. 2009 — Humanin: a novel central regulator of peripheral insulin action. — PLoS ONE — [Animal Studies]
• Lee C et al. 2013 — Humanin: a harbinger of mitochondrial-derived peptides?. — Trends in Endocrinology & Metabolism — [Review]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*